Eric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total value of $7,763,875.00. Following the sale, the chief executive officer directly owned 8,808,533 shares in the company, valued at $411,358,491.10. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

NASDAQ:TEM opened at $50.47 on Friday. The stock’s fifty day moving average is $48.73 and its 200 day moving average is $58.19. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The firm has a market capitalization of $9.06 billion, a PE ratio of -29.34 and a beta of 3.99. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter in the prior year, the firm posted ($0.24) EPS. Tempus AI’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Wednesday, March 11th. Morgan Stanley decreased their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. JPMorgan Chase & Co. decreased their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Mizuho assumed coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $68.64.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus introduced Tempus Preview, a new application designed to deliver rapid, clinically significant insights before final diagnostic results are available, which could improve oncology workflows and strengthen the company’s AI-driven precision medicine offering. Article Title
• Positive Sentiment: The company launched the PRECISION Challenge, a national research program that opens its foundation-model work to a broader scientific community, potentially expanding Tempus’ data ecosystem, visibility, and long-term research partnerships. Article Title
• Positive Sentiment: Investors are also reacting to Tempus’ latest ASCO-related AI and multimodal foundation-model updates, which reinforce the company’s positioning as a leader in AI for oncology and may support sentiment around future growth. Article Title
• Neutral Sentiment: There was also unusual call-option activity and analyst/investor-day commentary, suggesting traders are positioning for bigger moves, but these signals are not yet clear enough to indicate a lasting directional catalyst. Article Title
• Negative Sentiment: CEO Eric Lefkofsky sold 166,250 shares in a pre-arranged 10b5-1 plan, which can still weigh on sentiment because insider selling often raises concerns about near-term upside, even when the sale is routine. Article Title
• Negative Sentiment: Tempus remains a high-volatility, unprofitable company with negative margins and a heavy debt load, so investors may be cautious despite the recent product momentum.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the business. JPL Wealth Management LLC bought a new stake in shares of Tempus AI during the third quarter worth $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI during the fourth quarter worth $27,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Tempus AI during the third quarter worth $38,000. Tsfg LLC increased its stake in shares of Tempus AI by 1,515.2% during the third quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after buying an additional 500 shares during the period. Finally, Cloud Capital Management LLC purchased a new position in shares of Tempus AI during the third quarter valued at $44,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.